Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2/PHASE3
100 participants
INTERVENTIONAL
2024-10-09
2026-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The objective of this prospective diagnostic study is to evaluate the diagnostic efficacy of 18F-FAPI-74 PET/CT in patients with PC. The aim is to evaluate the sensitivity and specificity of 18F-FAPI-74 in detection of local lymph node metastasis and distant metastasis in patient level in patients with PC in primary staging and when suspected recurrence. 100 patients with PC are enrolled on whom PET/CT studies are performed with the novel 18F-FAPI-74 tracer. The data will be collected between 2024-2026.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
18F-FAPI PET Imaging in Pancreatic Adenocarcinoma
NCT05884463
Colon Cancer Diagnosis With FAPI-PET Imaging
NCT07272772
A Study Using 18F-FAPI PET to Evaluate Treatment Response in Pancreatic Adenocarcinoma
NCT06277206
PET-CT in Diagnosis of Pancreatic Cystic Neoplasms
NCT01317836
[68Ga]Ga-FAPI-46 Positron Emission Tomography (PET) Scan to Improve the Imaging of Pancreatic and Bile Duct Cancer
NCT05957250
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Staging
PET/CT
PET/CT with FAPI-74 tracer is performed.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PET/CT
PET/CT with FAPI-74 tracer is performed.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects must be male or female aged 18-85 years.
* WHO performance score 0-2.
* Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol.
Exclusion Criteria
* Study subject is not able to understand the purpose of the study.
* Medical conditions prohibiting whole-body PET/CT imaging.
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Turku University Hospital
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Saila Kauhanen, docent
Role: PRINCIPAL_INVESTIGATOR
University of Turku and Turku University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Turku PET Centre, Turku University Hospital
Turku, , Finland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Panca-FAPI
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.